

Area Prescribing Group report

Date: Friday 03 May 2024 Quorate: Yes

The items in this report are supported by the area prescribing group and approval by NHS Cheshire and Merseyside Integrated Care Board (ICB) is detailed below.

Document links provided for any APG recommendations are temporarily hosted on the legacy Pan Mersey APC website as a pragmatic solution until such time as a Cheshire and Merseyside APG website is available. The <u>legacy Cheshire formulary</u> will also be updated to reflect these changes.

CMAPG governance documents are now hosted on the new <u>Prescribing</u> section of the NHS Cheshire and Merseyside website, which is currently being developed

New medicines NICE TAS

Proposal	Notes	Approval
Dupilumab for treating moderate to severe prurigo nodularis RAG designation: Black APG subgroup: 12 April 2024 APG: 03 May 2024	Date of NICE TA publication: 13 March 2024 Approval for implementation: N/A Deadline for implementation: N/A RAG report in line with TA955. NICE does not recommend dupilumab for treating moderate to severe prurigo nodularis in adults. A Black RAG rating will be assigned in the formulary with a link to the NICE TA.	ICB Medicines Optimisation and Pharmacy (MOP) Group: 16 May 2024, approved by ICB Medicines Optimisation and Pharmacy Group.

New medicines other

Proposal	Notes	Approval
Tirzepetide for type 2 diabetes RAG designation: Green APG subgroup: 12 April 2024 APG: 03 May 2024	Minor update to cost section to replace single use pens with KwikPens. There is no change in costs. For clarity, a minor amendment has also been made about use with insulin on page 1.	ICB Medicines Optimisation and Pharmacy (MOP) Group: 16 May 2024, approved by ICB Medicines Optimisation and Pharmacy Group.
Targeted-release budesonide for treating primary IgA nephropathy RAG designation: Red APG subgroup: 12 April 2024 APG: 03 May 2024	For noting. Targeted release budesonide has recently been added to the 2024/25 high cost drugs list. This change affects reimbursement to Trusts for use of this drug but does not affect the RAG rating.	ICB Medicines Optimisation and Pharmacy (MOP) Group: 16 May 2024, noted by ICB Medicines Optimisation and Pharmacy Group.

Antimicrobials

Proposal	Notes	Approval
Primary care antimicrobial prescribing updates for adults: <u>balanitis</u> , <u>bites — human and animal</u> , <u>chickenpox</u> , <u>shingles</u> .	Recommendations identified for early harmonisation because of updates in national guidance, differences between legacy Cheshire and legacy Merseyside recommendations or safety concerns.	ICB Medicines Optimisation and Pharmacy (MOP) Group: 16 May 2024, approved by ICB Medicines Optimisation and Pharmacy Group.
RAG designation: not applicable. APG subgroup: 10 Apr 2024 APG: 03 May 2024		

APG reports

Title	Notes	Approval
NICE TA adherence checklist March 2024	For noting.	ICB Medicines Optimisation and Pharmacy (MOP) Group: 16 May 2024, noted by ICB Medicines Optimisation and Pharmacy Group.